Zydus Cadila has received the final approval from the USFDA to market Voriconazole Tablets in strengths of 50 mg and 200 mg. The drug will be produced at the group’s formulations manufacturing facility at Baddi in Himachal Pradesh.
The estimated sales for Voriconazole Tablets which is used in the treatment of fungal infections, is $92.8 million, as per IMS (MATMarch 2016).
The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
